SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and tests of key support levels dominate discussion, with many traders fearing further downside while others argue the market is oversold and see a potential bottom. Traders also point to ETF outflows, macroeconomic pressure, and exchange-security concerns as possible headwinds, but no single explanation is clearly established.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline alongside a broader crypto-market selloff has put the psychologically important $1 level in focus, with traders watching for a break and citing weak risk appetite and leveraged liquidations. The community is split between expecting further losses and treating the dip as an opportunity to accumulate.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA decision on ivonescimab for EGFR-mutated lung cancer is the focus, with traders debating whether strong progression-free-survival results and favorable updated survival trends can offset the trials missed statistical-significance threshold for overall survival. Bulls cite AstraZenecas investment and the broader drug prospects as signs of confidence, while bears see meaningful rejection risk, making the event a high-stakes, binary catalyst.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadias NUPLAZID formulation-patent appeal is the main focus, with traders debating whether the appellate court will uphold favorable lower-court rulings or threaten the drugs long-term exclusivity. The legal uncertainty has fueled sharp selling and a rebound, while bullish voices point to growth in DAYBUE and NUPLAZID as support for the business beyond the court decision.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,827,248.80032983 in circulation. The last known price of Litecoin is 49.45346856 USD and is down -1.54 over the last 24 hours. It is currently trading on 1567 active market(s) with $228,945,256.48 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoin is drawing attention amid a sharp selloff and persistent concerns about weak price action and lost support, with traders debating whether the decline signals further downside or a buying opportunity. Some holders are accumulating and expecting a rebound, while skeptics point to LTCs repeated tendency to give back gains and lag other cryptocurrencies.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: U.S. Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, U.S. Rod and Refining, Atlantic Copper, and Corporate and Other. The U.S. Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The U.S. Rod and Refining segment consists of copper conversion facilities located in North America and includes refinery and rod mills. The Atlantic Copper segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

FCX is under pressure as traders focus on weaker copper prices and reduced sales guidance amid concerns about the Grasberg ramp-up, despite an earnings beat. The community is split between seeing the decline as a buying opportunity based on long-term copper demand and warning that near-term weakness could continue.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention for a sharp, volatile pullback after a major prior rally, amid broader crypto weakness and reports of leveraged liquidations. Traders are split between calling the decline an oversold buying opportunity and expecting further losses, with many questioning whether ZEC can regain support.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMAs stronger-than-expected Q3 results, led by accelerating ASCENIV growth and a higher earnings outlook, drove a sharp share-price rebound and renewed bullish discussion. Traders are debating whether the growth can sustain a broader rerating, while some point to lingering skepticism and weak follow-through; buyout talk remains speculation.

Corteva, Inc. is a global pure-play agriculture company that combines innovative technologies, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. It generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. The company leverages recognized agricultural brands and a robust technology pipeline to maximize productivity for farmers while working with stakeholders throughout the food system to fulfill its promise of enriching the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva was founded in 1802 and is headquartered in Indianapolis, IN.

Corteva Inc

Cortevas quarterly update and weaker outlook, tied to soft Brazilian demand, elevated channel inventories and delayed purchases, are driving attention after a sharp selloff. Traders are split between viewing the decline as justified by deteriorating agricultural fundamentals and calling it an overreaction with room for a recovery.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.00059373 USD and is down -1.77 over the last 24 hours. It is currently trading on 194 active market(s) with $2,220,767.91 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

AMP is drawing attention after a sharp, high-volume price run that traders describe as unusual, with some pointing to strength during a broader crypto-market decline. The move has prompted dip-buying and breakout speculation, alongside skepticism that it may fade as a short-lived pump; no clear confirmed catalyst dominates the discussion.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

Equity

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Vanguard International Equity Index Funds - Vanguard FTSE All-World Ex-US Small Capital Index Fund ETF

Bullish Sentiment

Bausch Health Companies Inc. shares (BHC) jumped over 7% in after-hours trading on Wednesday following a solid fourth-quarter earnings report that beat revenue estimates and reaffirmed strong guidance for 2025.The company posted Q4 revenue of $2.56 billion, surpassing the consensus estimate of $2.51 billion, while adjusted earnings per share (EPS) of $1.14 narrowly topped expectations of $1.13.&nbsp;Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $935 million, up from $869 million a year ago.CEO Thomas Appio highlighted 2024 as a year of "delivering on our commitments," with results landing at the high end of revenue guidance and exceeding expectations for adjusted EBITDA (excluding Bausch + Lomb) and operating cash flow.Salix, the company's gastrointestinal and hepatology division, generated $634 million in Q4 revenue, up 9% year-over-year. This was largely driven by Xifaxan, a treatment for irritable bowel syndrome and traveler's diarrhea, which posted 16% growth.&nbsp;The Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.For 2025, Bausch Health projects revenue between $9.90 billion and $10.15 billion, above the consensus estimate of $9.89 billion.&nbsp;The company also forecasts FY25 adjusted EBITDA between $3.525 billion and $3.675 billion.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BHC_sentiment_and_message_volume_Feb_19_07562dbe77.png" alt="BHC sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>BHC sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned 'extremely bullish' following the earnings report, with message volume spiking 1,900% on Wednesday.One user highlighted "very good organic revenue growth and solid guidance," expecting a strong bounce for the stock.&nbsp;Another hoped for a rally past $20 per share.<stembedurl>https://stocktwits.com/Neildc/message/604885428</stembedurl><stembedurl>https://stocktwits.com/Maxgluteal/message/604910108</stembedurl>However, BHC shares remain about 35% below analysts' average target price of $8.83.&nbsp;The stock has lost over 19% year-to-date.&nbsp;&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bausch Health Companies Inc

Bausch + Lomb Corp.

VanEck Pharmaceutical ETF

Vanguard FTSE All-World Ex-US Small Cap ETF

Vanguard Total International Stock ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

VSS Vanguard FTSE All-World Ex-US Small Cap ETF

Fundamentals

Latest VSS News